We would love to hear your thoughts about our site and services, please take our survey here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDVRG.L Regulatory News (DVRG)

  • There is currently no data for DVRG

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

2022 Revenue Update

9 Jan 2023 07:00

RNS Number : 0134M
Deepverge PLC
09 January 2023
 

 

9 January 2023

 

DeepVerge PLC

 

("DeepVerge" or "the Company" or "the Group")

 

2022 Revenue Update

 

DeepVerge plc (AIM: DVRG), announces that the Company's unaudited revenues for 2022 were approximately £17.2m, slightly below market expectations, although £18m would have been achieved but for a significant element of recently signed contracts now falling for delivery in the current year. This still represents a significant increase year on year (2021 Revenue (audited) £9.3m, 2020 Revenue (audited) £4.4m) despite some delays into 2023 due to supply chain issues. Licence revenues featured strongly as the Group moves progressively from small and medium ticket equipment sales to larger £1m+ data and AI focused sales through partners.

 

For the past 24 months, Modern Water, a business unit of DeepVerge, has been focused on building high-value solutions for monitoring water and wastewater using advanced software and data automation underpinned by its established equipment range. 

 

In addition, the Company is moving its Labskin business deeper into data and AI with the creation of Skin Trust Club, with its focus on a personalised skincare platform for partners and building a large skin microbiome database for its corporate customers.

 

These moves are in parallel with a refocusing of the business on tier-one partnerships that sell and support DeepVerge solutions in their core markets where they are dominant or major participants.

 

This has led to significant contracts and order book with a wide range of government institutions in multiple territories. These include US Government agencies, IARPA, NOAA, and Georgia Port Authority in the United States where DeepVerge is focusing Labskin, Skin Trust Club and environmental microbiome sequencing efforts. The Modern Water business is increasingly focused on the developing world with business and multiple orders across the Middle East, China, South and Central Asia and North Africa providing solutions in markets that are under pressure from pollution and water scarcity.

 

The accelerated Group restructuring announced on 22 November 2022 has created separate businesses with clear domain focus, with the personnel and resources necessary to support the growth being experienced and anticipated. The restructuring also brought certain key logistical processes in-house, better to serve customers and partners and to protect against worldwide supply chain shocks. As well as focus, this restructuring is also expected to deliver considerable cost savings in 2023 of up to £2m.

 

Dr Nigel Burton, interim CEO DeepVerge plc, commented:

"The Group's major achievements of 2022 were:

· Intensifying the focus on bigger ticket, higher value, technology and data-based sales;

· Gaining the confidence of partners and their customers to use our solutions;

· Putting in place the personnel and resource structures needed to support and develop this type of expanding business; and

· Bedding in reference sites across the globe which showcase the solutions we can deliver to customers.

These achievements, and the successful fund raise in November 2022, provide solid foundations for 2023. I'd like to thank our shareholders, customers, partners and employees for their support in 2022."

 

DeepVerge plc

Nigel Burton, Interim CEO

+44 (0) 1904 40 4036

 

SPARK Advisory Partners Limited

(Nominated Adviser)

 

Neil Baldwin

+44 (0) 113 370 8974

Turner Pope Investments (TPI) Limited (Broker)

Andy Thacker/James Pope

+44 (0) 20 3657 0050

 

Market Abuse Regulation (MAR) Disclosure

 

THIS ANNOUNCEMENT CONTAINS INSIDE INFORMATION AS STIPULATED UNDER THE UK VERSION OF THE MARKET ABUSE REGULATION NO 596/2014 WHICH IS PART OF ENGLISH LAW BY VIRTUE OF THE EUROPEAN (WITHDRAWAL) ACT 2018, AS AMENDED. ON PUBLICATION OF THIS ANNOUNCEMENT VIA A REGULATORY INFORMATION SERVICE, THIS INFORMATION IS CONSIDERED TO BE IN THE PUBLIC DOMAIN.

 

About DeepVerge plc (www.deepverge.com)

DeepVerge is an environmental and life science group of companies that develops and applies AI and IoT technology to analytical instruments for the analysis and identification of bacteria, virus and toxins; Utilising artificial intelligent data analytics to scientifically prove the impact of skincare product claims on skin.

 

 

 

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
UPDSSSFWAEDSELF
Date   Source Headline
27th Dec 20237:00 amRNSCancellation - DEEPVERGE PLC
20th Dec 202312:30 pmRNSUpdate; exclusivity agreement with Microsaic
13th Dec 20234:38 pmRNSUpdate
14th Sep 20237:00 amRNSNew Website, Update
7th Aug 20232:30 pmRNSDisposal;Update; Related Party Trans'n-replacement
7th Aug 20237:00 amRNSDisposal; Update
2nd Aug 20239:35 amRNSBoard Change
1st Aug 20237:00 amRNSCompany Secretary Change
12th Jul 20237:00 amRNSUpdate
5th Jul 202311:26 amRNSUpdate
26th Jun 20237:30 amRNSSuspension - Deepverge PLC
26th Jun 20237:00 amRNSSale or closure of subsidiaries; share suspension
5th Jun 20237:00 amRNSCost reductions;delay to Ann. Report;New contract
19th Apr 20231:21 pmRNSMicrosaic Creditor; Update
17th Apr 20237:00 amRNS2022 revenue update - revision
24th Mar 202310:24 amRNSChange of Auditor
6th Mar 20234:35 pmRNSPrice Monitoring Extension
6th Mar 20232:05 pmRNSSecond Price Monitoring Extn
6th Mar 20232:00 pmRNSPrice Monitoring Extension
22nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
22nd Feb 20234:35 pmRNSPrice Monitoring Extension
7th Feb 20237:00 amRNSBoard Appointment
6th Feb 20235:30 pmRNSSignificant contract win and Board change
2nd Feb 20234:40 pmRNSSecond Price Monitoring Extn
2nd Feb 20234:35 pmRNSPrice Monitoring Extension
9th Jan 20237:00 amRNS2022 Revenue Update
23rd Nov 20224:10 pmRNSTR-1: Notification of major holdings
22nd Nov 20227:00 amRNSAccelerated Restructuring
16th Nov 20229:00 amRNSDirector/PDMR Shareholding
14th Nov 202212:16 pmRNSResult of Meeting
11th Nov 20224:37 pmRNSHolding(s) in Company
7th Nov 20227:00 amRNSDirectorate and Management Changes
3rd Nov 202212:32 pmRNSDirectorate Change
1st Nov 20223:56 pmRNSResult of Broker Offer; Total Voting Rights
31st Oct 20222:23 pmRNSBroker Offer to raise a max of £2.5m - replacement
31st Oct 20222:18 pmRNSExtension of Broker Offer to 430pm on 31 October
28th Oct 20221:06 pmRNSExtension of Broker Offer
27th Oct 20227:01 amRNSBroker Offer to raise a maximum of £2.5m
27th Oct 20227:00 amRNS£10m Placing, Broker Option, RPTs, Notice of GM
25th Oct 20222:05 pmRNSSecond Price Monitoring Extn
25th Oct 20222:00 pmRNSPrice Monitoring Extension
25th Oct 20227:01 amRNSUpdate - Proposed Financing,Proposed Board Changes
25th Oct 20227:00 amRNSHistorical Related Party Transactions
12th Oct 20224:41 pmRNSSecond Price Monitoring Extn
12th Oct 20224:35 pmRNSPrice Monitoring Extension
12th Oct 20227:04 amRNSResponse to Market Speculation
11th Oct 202211:05 amRNSSecond Price Monitoring Extn
11th Oct 202211:00 amRNSPrice Monitoring Extension
4th Oct 20227:00 amRNSLabskin contract
30th Sep 20224:41 pmRNSSecond Price Monitoring Extn

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.